LACTOLOGY FOUNDATION

Medicinal charcoal, combinations (ATC A07BA51) comprises intestinal adsorbent products that contain activated (medicinal) charcoal together with one or more additional active substances, used mainly for common diarrhea and digestive symptoms, with negligible charcoal absorption and generally low expected risk in breastfeeding, subject to evaluation of the co‑ingredients.atcddd.fhi+2

ATC A07BA51 overview

ATC code A07BA51 designates “medicinal charcoal, combinations” within the subgroup A07BA Charcoal preparations, itself part of the A07 intestinal adsorbents class of antidiarrheals and intestinal anti‑infective/anti‑inflammatory agents. The defined daily dose for charcoal preparations in this group is based on treatment of common diarrhea, not on high‑dose use for poisoning.atcddd.fhi+2

Composition and typical co‑ingredients

A07BA51 products contain medicinal activated charcoal as the primary adsorbent, combined with other substances such as mineral salts (for example calcium carbonate), mild antacids, or adjuncts aimed at reducing flatulence or supporting digestion. Some combinations are marketed as dietary supplements rather than strictly medicinal products, but they retain the pharmacological profile of an intestinal adsorbent dominated by charcoal.drugs+3

Mechanism of action

The therapeutic effect of A07BA51 combinations is largely driven by activated charcoal, whose highly porous carbon structure provides a large surface area for adsorption of drugs, bacterial toxins, gases, and other xenobiotics in the gastrointestinal lumen. Co‑ingredients may contribute additional effects, such as neutralization of gastric acid or binding of gas, but they do not change the fundamental local, non‑absorptive mechanism of charcoal.webmd+3

Therapeutic indications

Medicinal‑charcoal combinations A07BA51 are indicated primarily for symptomatic treatment of common, usually self‑limited diarrhea and for relief of bloating and excessive flatulence after meals. They may be used in adults and older children as adjuncts to standard measures such as fluid and electrolyte replacement, not as substitutes for rehydration therapy.atcddd.fhi+3

Dosage and exposure context

The daily charcoal dose in A07BA51 products for diarrhea and flatulence typically aligns with the 5 g DDD defined for charcoal preparations in A07BA, although individual products may recommend split doses before and after meals. Even when co‑formulated, the total amount of charcoal remains far below the large single doses used in acute poisoning, which further limits any systemic or lactation‑related concerns.atcddd.fhi+4

Pharmacokinetics relevant to lactation

Activated charcoal is not absorbed from the intact gastrointestinal tract; it remains within the intestinal lumen and is eliminated unchanged in the feces. Accordingly, systemic charcoal exposure in the breastfeeding mother is negligible, and clinically meaningful transfer into human milk is not expected.ncbi.nlm.nih+2

Maternal safety profile

Adverse effects of charcoal‑containing combinations are similar to single‑ingredient medicinal charcoal and include black stools, constipation, nausea, or vomiting; high or prolonged doses may rarely cause intestinal obstruction. Product‑specific risks may arise from co‑ingredients such as sorbitol (risk of diarrhea and dehydration) or high calcium loads, so contraindications and cautions listed in the summary of product characteristics should be followed.drugs+3

Lactation safety assessment

General pharmacological guidance for breastfeeding indicates that non‑absorbed oral drugs have minimal potential to reach breast milk and are usually compatible with lactation. For A07BA51, the charcoal component therefore represents very low risk; however, overall lactation safety depends on the specific additional active substances, which should be checked individually (for example in LactMed or specialized lactation references) if they have systemic bioavailability.research.rug+4

Potential effects on the breastfed infant

Direct exposure of the infant to activated charcoal from maternal use of A07BA51 is expected to be negligible, making charcoal‑related toxicity via milk highly unlikely. Any potential infant risk more plausibly comes from co‑ingredients that reach maternal circulation and milk, or from the underlying maternal illness (infectious diarrhea), which may warrant monitoring of the infant for stool changes, fever, or dehydration.pure.eur+4

Practical recommendations during breastfeeding

In breastfeeding women, short‑term use of medicinal charcoal combinations at recommended doses for mild diarrhea or postprandial flatulence is usually acceptable, provided that co‑formulated actives are individually assessed and judged compatible with lactation. Breastfeeding generally need not be interrupted or timed around doses, but clinicians should avoid prolonged or unnecessary use, verify that there are no high‑risk co‑ingredients, and document both maternal benefit and any infant monitoring.atcddd.fhi+6

Risk–benefit balance

For appropriately selected products and indications, A07BA51 medicinal‑charcoal combinations offer localized gastrointestinal symptom relief with very low charcoal‑related lactation risk, leading to a favorable risk–benefit profile in breastfeeding when co‑ingredients are compatible. The main determinants of safety are accurate diagnosis, respect of contraindications, careful review of the additional actives, and adherence to evidence‑based principles for medicine use in lactating women.atcddd.fhi+7